From GlobeNewswire: 2025-01-28 22:31:17

89bio, Inc. announced the pricing of its public offering, totaling approximately $250.0 million. The offering includes 21,671,428 shares of common stock and pre-funded warrants. The underwriters have an option to purchase additional shares. The company is focused on developing therapies for liver and cardiometabolic diseases. 89bio’s lead candidate, pegozafermin, is currently in Phase 3 clinical development for metabolic dysfunction-associated steatohepatitis and severe hypertriglyceridemia. The offering is expected to close on January 30, 2025. Goldman Sachs & Co. LLC, Leerink Partners, and BofA Securities are acting as lead book-running managers for the offering.

For more information, visit the SEC’s website or contact the lead book-running managers. This press release does not constitute an offer to sell securities. Forward-looking statements in this release are subject to various risks and uncertainties. 89bio disclaims any obligation to update these statements. For investor inquiries, contact Annie Chang at [email protected]. For media inquiries, contact Sheryl Seapy at [email protected].



Read more at GlobeNewswire: 89bio, Inc. Announces Pricing of $250.0 Million Public